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Abstract
Detection of the Mycobacterium tuberculosis cell wall antigen lipoarabinomannan (LAM) in urine permits diagnoses
of tuberculosis (TB) to be made in HIV-infected patients with advanced immunodeficiency. This can be achieved at
the point-of-care within just 30 minutes using the Determine TB-LAM, which is a commercially available, lateral-flow
urine ‘strip test’ assay. The assay has been shown to have useful diagnostic accuracy in patients enrolling in
antiretroviral treatment services or in HIV-infected patients requiring admission to hospital medical wards in
sub-Saharan Africa. Such patients have high mortality risk and have most to gain from rapid diagnosis of TB
and immediate initiation of treatment. However, few studies using this assay have yet been reported and many
questions remain concerning the correct use of the assay, interpretation of results, the role of the assay as an
add-on test within existing diagnostic algorithms and the types of further studies needed. In this paper we
address a series of questions with the aim of informing the design, conduct and interpretation of future
studies. Specifically, we clarify which clinical populations are most likely to derive benefit from use of this assay
and how patients enrolled in such studies might best be characterised. We describe the importance of employing a
rigorous microbiological diagnostic reference standard in studies of diagnostic accuracy and discuss issues surrounding
the specificity of the assay in different geographical areas and potential cross-reactivity with non-tuberculous
mycobacteria and other organisms. We highlight the importance of careful procedures for urine collection and storage
and the critical issue of how to read and interpret the test strips. Finally, we consider how the assay could be used in
combination with other assays and outline the types of studies that are required to build the evidence base
concerning its use.
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Background
HIV-associated tuberculosis (TB) remains a major chal-
lenge to global health with an estimated 1.1 million new
cases and 430,000 deaths in 2011 [1]. A majority of cases
(79%) are in sub-Saharan Africa where health infrastruc-
ture and laboratory services are least well developed to
tackle this challenge. Post-mortem studies conducted among
hospital in-patients who died with HIV/AIDS in Africa
have reported the presence of TB (often disseminated) in
between 30% and 50% of cadavers [2-5]. Much of this
disease remained undiagnosed at the time of death,
highlighting the enormous challenge of TB screening
and diagnosis in those with HIV infection. However, in
recent years, new assays have been developed and evalu-
ated and have been demonstrated to have utility among
HIV-infected patients. These include the Xpert MTB/RIF
automated rapid molecular assay (Cepheid Inc., Sunnyvale,
CA, USA) [6,7] and the Determine TB-LAM (Alere Inc.,
Waltham, MA, USA) lateral flow urine antigen test [8].
The Xpert MTB/RIF assay, which was endorsed by
the World Health Organization (WHO) in 2010, has
much greater sensitivity than sputum smear microscopy
in HIV-infected patient populations and is now being
increasingly implemented in many resource-limited coun-
tries [7]. However, while this is undoubtedly a landmark
development in TB diagnostics, its relatively high cost
and the need for sophisticated instrumentation, reliable
power supply and linkage to a computer will limit its
use. Unfortunately, it does not fulfil many of the ideal
characteristics of a point-of-care test and its use will
likely be confined largely to the laboratory environment
[7]. Separation of testing from the clinical interface may
undermine potential impact on clinical outcomes since
the scope for same-day decision making regarding ini-
tiation of TB treatment is limited [9,10]. This may be
particularly problematic in settings with a high rate of
initial default and especially among HIV-infected pa-
tients with advanced immunodeficiency in whom de-
lays in diagnosis may be associated with considerable
mortality risk [11].
The Determine TB-LAM assay diagnoses TB by detecting
the presence of the Mycobacterium tuberculosis cell
wall antigen lipoarabinomannan (LAM) in urine of HIV-
infected patients [8]. Despite having lower sensitivity
compared to the Xpert MTB/RIF assay [12], the main
advantages of the Determine TB-LAM test are its sim-
plicity of use, lack of instrumentation, speed of use with
results available after 25 minutes, low cost (initially mar-
keted at $3.50 per test) and the fact that it has the po-
tential to be implemented at the point-of-care. These
characteristics make this potentially a very useful ‘add-on
test’ within the TB diagnostic algorithm. Shortened time
to initiation of treatment in patients with HIV-associated
TB reduces mortality risk [13] and rapid point-of-care
diagnostics are likely to be the best means of achiev-
ing this.
Earlier studies evaluating the enzyme-linked immuno-
sorbent assay (ELISA) format of the urine LAM assay
have previously been summarized and reviewed [8,14]
but far fewer data are available regarding the use of the
Determine TB-LAM lateral flow version of the assay.
Currently available data on the diagnostic accuracy of
Determine TB-LAM from published studies or recent
conference proceedings are summarized in the Table 1.
These data largely confirm that the sensitivity of Deter-
mine TB-LAM is greatest among HIV-infected patients
with the most advanced immunodeficiency. However,
there is considerable heterogeneity in the data from studies
of both the ELISA and lateral flow versions of the assay.
This may relate to differences in the patient populations
studied or to methodological or technical issues which
are discussed later in this article. These issues require
careful consideration when interpreting results and must
be taken into account when designing further studies.
Following its commercial launch in January 2013,
Determine TB-LAM remains the focus of ongoing clinical
evaluation studies. As the evidence base grows, data on
this assay may be reviewed by an expert panel convened
by the WHO – potentially in 2014. Below we address
key issues that need to be carefully considered in further
evaluations of this assay which we present as a series of
questions. We hope that this paper will help to inform
the design, conduct and interpretation of future clinical
studies and accelerate the expert review process. The
opinions expressed in this article are those of the individ-
uals represented in the authorship and are based upon the
evidence base available at the time of writing. Many of
the data referred to are from studies conducted by the
authors, providing a perspective of those working dir-
ectly in this field of research.
Main text
1. Which patient populations should be prioritized for
further study of Determine TB-LAM?
Current evidence strongly indicates that the urine LAM
antigen assays only have useful diagnostic accuracy among
HIV-infected adult patients and should not be used to
investigate those who are HIV-negative [14]. There are
currently no published data from studies in children.
In addition, assay sensitivity is strongly related to the
degree of immunodeficiency, with graded increases in
sensitivity with diminishing CD4 counts. Current evidence
shows that the ELISA and the lateral flow formats of
the assay do not have useful diagnostic accuracy among
patients with CD4 counts greater than approximately
200 cells/μL or among those who have early clinical stages
of disease (WHO stages 1 or 2) prior to TB diagnosis.
Thus, the specific clinical populations in which the assay
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Table 1 Studies reporting on the diagnostic accuracy of the determine TB-LAM assay
Study Location Patient population No. of
patients
screened
Median CD4
count (IQR)
Number of
TB cases
(PTB/EPTB)
Reference
standard
Urine testing
(retrospective
or prospective)
Overall
sensitivity
n/N (%)
Sensitivity by
CD4 count
n/N (%)
Overall
specificity
n/N (%)
Results by
grade 1
or grade 2
cutoff
Lawn et al.
(2012) [7]
Cape Town,
South Africa
Active screening
of HIV + outpatients
pre-ART
516
170
(100–233)
PTB = 85
Sputum culture
(liquid)
Retrospective 24/85 (28.2)
<50: 12/18
(66.7)
425/431
(98.6)
Grade 1
<100: 15/29
(51.7)
<200: 23/59
(39.0)
≥200: 1/25
(4.0)
Peter et al.
(2012) [15]
Cape Town,
South Africa
Inpatient HIV +
TB suspects
281 TB
suspects
+88 non-TB
controls
90
(47–197)
PTB + EPTB =
116
Sputum and
non-sputum
culture (liquid)
Retrospective
Grade 1 cutoff:
77/116 (66)
Grade 1
cutoff:
Grade 1
cutoff:
79/88 (89.8)†
Grade 1 and
2 reported
≤200: 58/81
(72)
>200: 14/26
(54)
Grade 2 cutoff:
58/116 (50)
Grade 2
cutoff:
Grade 2
cutoff:
87/88 (98.9)†
≤200: 47/81
(58)
>200: 7/26
(27)
Dorman et al.
(2012) [16]
Cape Town,
South Africa
and Kampala,
Uganda
Inpatient and
outpatient HIV +
TB suspects
997
152
(41-337)
Total cases = 16
Sputum
culture (solid
and liquid), +
mycobacterial
blood culture
Prospective 136/367 (37.1)
≤100: 116/196
(59.2)
559/573
(97.6)
Grade 2
PTB = 243
PTB + mycobact-
eremia = 108
>100: 20/169
(11.8)
Mycobacteremia
alone = 16
Van Rie et al.
(2013) [17]
Johannesburg,
South Africa
Mostly inpatient HIV +
disseminated TB and
EPTB suspects who
could not produce
sputum sample or
were sputum smear
and sputum Xpert
negative (17% of
patients NOT HIV+)
219
116
(34–221)
EPTB +
disseminated =
51
Culture
(sputum,
blood,
lymph node
FNA, CSF
pleural fluid,
ascitic fluid,
urine)
Not stated
Any positive
culture- 35/51
(68.8)
In HIV-
positives:
Any positive
culture: (91.8)
Grade 2
<100: 82.6%
100–199:
63.3%
≥200: 40.0%
In HIV
negatives: 0%
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Table 1 Studies reporting on the diagnostic accuracy of the determine TB-LAM assay (Continued)
Drain et al.
(2013) [18]
Durban,
South Africa
Newly diagnosed
HIV + out-patients
342
180
(73–311)
60 PTB (positive
microbiology)
Sputum smear
or culture or
Positive
microbiology
+ clinical
diagnoses
Prospective
PTB (micro+)
only: 17/60
(28.3)
PTB (micro+)
only:
No micro +
PTB diagnosis:
254/282 (90.1)
Unkown
<100: 12/32
(37.5)
100-199: 3/12
(25.0)
200-349: 1/3
(33.3)
≥350: 1/5
(20.0)
99 including PTB
+ EPTB + clinical
diagnoses
All diagnoses:
24/99 (24.2)
All diagnoses
No TB
diagnosis:
222/243
(91.2%)
<100: 14/50
(28.0)
100-199: 4/20
(20.0)
200-349: 2/6
(33.3)
≥ 350: 2/11
(18.2)
Shah et al.
(2013) [19]
Uganda Inpatient and
outpatient
HIV + TB
suspects 101 TB cases +
105 TB suspects
with TB excluded
60 among
those with
TB
103 PTB + EPTB
Sputum
culture (solid
and liquid),
mycobacterial
blood culture
Retrospective 50/103 (48.5)
<50:30/46
(65.2)
102/105
(97.1)
Grade 2
51-100: 12/17
(70.6)
101-200: 4/19
(21.1)
>200: 4/21
(19.0)
†Specificity reported is for a control group of non-TB suspects to illustrate differences between grade 1 and 2 cut-offs.
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might be useful include hospital in-patients with known
HIV infection [15] and ambulatory out-patients with
known HIV-infection and low CD4 cell counts such as
those newly referred to antiretroviral treatment (ART)
clinics [12]. The assay should not be used to screen or
investigate unselected patients in primary care as the
positive predictive value is very limited among those
who are either HIV-infected and have high CD4 counts
or who are HIV-negative.
2. What patient characterization helps interpretation of
study data?
In addition to HIV status and CD4 cell count, the sensitiv-
ity of Determine TB-LAM varies substantially according
to disease severity as reflected by a range of other prog-
nostic indices [16,20-23]. Thus, careful characterization
of the study population may help with data interpret-
ation and with assessment of the external validity of the
data. In general, the sicker patients are, the greater the
sensitivity of Determine TB-LAM. LAM-positive TB is
associated with more advanced WHO stages of disease
and higher Modified Early Warning Scores (MEWS),
which are both simple clinical assessments of disease
severity [21]. Higher sensitivity is found in hospital in-
patients compared to ambulatory out-patients [16] and
sensitivity is positively correlated with serum concen-
trations of serum C-reactive protein (CRP) [22], which
is a strong prognostic marker [20,24]. Higher sensitivity is
also strongly associated with increasing severity of an-
aemia and with more advanced symptoms in patients
with HIV-associated TB (Lawn SD, unpublished data).
Thus, careful characterisation of patient populations using
parameters such as symptom profile, CD4 cell count,
blood haemoglobin, body mass index, C-reactive protein
as well as simple validated illness severity and morbidity
tools such as MEWS or APACHE scores in studies of
in-patients may help with the interpretation and com-
parison of study data in future studies.
3. What is the appropriate reference standard in studies
of diagnostic accuracy?
Obtaining appropriate clinical samples and the use of
optimum microbiological methods to provide a rigorous
reference standard is a critical issue. Most existing studies
evaluating the diagnostic accuracy of LAM assays have
used sputum culture alone as the microbiological refer-
ence standard. This approach is potentially problematic
as false-negative reference standards could arise in pa-
tients in whom it is difficult to obtain sufficiently high
quality sputum samples, in those with HIV-associated
TB who do not have pulmonary involvement and also
due to variation in sputum processing protocols, includ-
ing stringency of sputum decontamination procedures.
These issues are likely to be particularly important in
HIV-infected patient populations as bacillary load in
sputum is typically low. Culture of multiple clinical samples
including sampling from sites of disease for extrapulmonary
TB will enhance the reference standard. These should be
tested in quality-assured laboratories using liquid cul-
ture which has the highest sensitivity for Mycobacterium
tuberculosis of any assay.
Sputum samples should be carefully obtained (this might
be aided by sputum induction using nebulized hypertonic
saline [25,26]) and more than one sputum sample should
ideally be tested in light of the significant incremental yield.
Simple patient instruction by healthcare workers on how
to correctly expectorate sputum is also an important inter-
vention to improve sample quality, especially in settings
without sputum induction facilities. When compared with
sputum induction in a primary care setting, it was found
to offer equivalent diagnostic yields with lower cost and
fewer adverse events when investigating initially smear-
negative or sputum-scarce TB patients using smear mi-
croscopy or Xpert MTB/RIF to test additional sputum
samples [27]. Additional extrapulmonary samples such
mycobacterial blood cultures [28] or fine needle lymph
node aspirates [29,30] might also be obtained for culture
or Xpert MTB/RIF testing. Moreover, testing of urine
using Xpert MTB/RIF or culture may provide a further
logical addition to the reference standard [31,32]. Al-
though LAM-antigenuria has been found to co-exist with
mycobacteriuria in a substantial proportion of patients
[31,33], antigenuria may also be present in urine testing
negative with Xpert MTB/RIF. Thus, simply testing urine
for the presence of M. tuberculosis cannot be used as the
sole reference standard.
A comprehensive microbiological assessment is the ideal
reference standard as this excludes the considerable
uncertainties that inevitably surround clinical and radio-
logical diagnoses. But in practice, obtaining multiple high
quality samples on large cohorts of patients is challenging
and very expensive. Clinical and radiological assessments
are often recorded, but reliance on non-microbiologically
confirmed TB diagnoses and responses to TB treatment
is a less robust approach. Patients with bacterial sepsis
such as pneumococcal pneumonia, for example, may
respond to rifampicin-containing TB treatment and im-
provements in clinical condition may be confounded
by other factors such as the initiation of ART. Moreover,
prospective follow-up may be complicated by new onset
incident TB.
4. Do non-tuberculous mycobacteria cause
false-positive results?
LAM encompasses a large family of related molecules
which are expressed by mycobacterial species and so cross-
reactivity between the assay antibodies and non-tuberculous
mycobacterial antigen is possible [8]. This is therefore a
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potential source of diminished assay specificity. Although
a small number of patients have been reported in studies
as having false-positive urine LAM results and have had
non-tuberculous mycobacteria cultured from sputum
samples, it is not clear whether these organisms were
true pathogens or sputum contaminants [8]. Studies in
which detection of LAM has been assessed in patients
with confirmed non-tuberculous mycobacterial pulmon-
ary or disseminated disease are lacking. Future studies
of the diagnostic accuracy of Determine TB-LAM studies
should ideally report on the species of the cultured isolates
of non-tuberculous mycobacteria and carefully seek to
determine the clinical significance of these isolates.
5. Is high assay specificity limited to studies in South Africa?
Many of the studies on TB diagnosis using urine LAM
assays have been done in South Africa with most others
being from other southern and east African countries.
Comparable studies using the LAM ELISA format of the
assay done within South Africa found specificity to lie
in the range 96% to 100% [12,34-37] whereas several
studies from Tanzania, Zimbabwe and India reported
specificities of 88% - 89% [38-40]. The reasons for this
have not been conclusively defined. However, it has been
speculated that a range of factors that might have con-
tributed to lower observed specificity in the latter studies
might include the use of solid rather than liquid culture
as the reference standard, investigation of predominantly
HIV-uninfected patients with a lower pre-test probability
of TB (an ‘off-label’ indication for the assay), use of non-
sterile containers to store urine and the higher frequency
of cultures of non-tuberculous mycobacteria [8]. An im-
portant observation from a multi-country study using
standardized methodology was that the specificity of
Determine TB-LAM did not differ between South African
and Ugandan study sites [16], which provides important
reassurance about assay performance in different geo-
graphical settings. However, many more studies are needed
in different countries and regions.
6. How should urine samples be collected and stored?
Anti-LAM antibodies used in the commercial LAM
assays cross-react with a number of other bacteria, in-
cluding those present in oral flora such as various species
of Actinobacteria (Nocardia and Streptomyces), Candida
[36] and non-tuberculous mycobacteria [8]. Cross-reactive
bacteria from the perineum or in faecal material could
contaminate urine samples as might environmental or-
ganisms present in non-sterile urine collection dispos-
ables and containers. Obtaining urine samples in studies
of very young children may be particularly challenging.
The presence of such organisms is likely to become increas-
ingly important if samples are left at room temperature for
prolonged periods, permitting microbial replication. Thus,
collection of a clean sample should be done following
careful instruction to the patient. Whether this should be
a mid-stream sample has yet to be defined but sterile con-
tainers should be used. Some data suggest that concentra-
tions of LAM spiked into urine samples are stable for the
first 2 hours but that they deteriorate after this [41]. One
of the authors (SDL) has found considerable loss of LAM
reactivity of urine samples stored for 3 years at −20°C and
following at least 2 freeze-thaw cycles (unpublished data).
Thus, we recommend that samples be tested immediately.
If this is not possible, samples should be stored by freezing
as soon as possible following sample collection and that
freeze-thaw cycles are minimized. A series of carefully
conducted analytic studies is needed to address these issues.
7. How should determine TB-LAM test strips be interpreted?
Interpretation of lateral-flow assays designed to provide
a binary (positive / negative) result can be challenging [42].
The Determine TB-LAM product insert accompanying
the assay at the time of its commercial launch in 2013
did not provide clear guidance regarding how to pre-
cisely interpret the test strip results. The assay includes
a reference card with bands of graded intensity to facili-
tate the reading of results. In the literature, one research
group has referred to the least intense band as the ‘grade 1
cut-point’ and the band of next intensity has been termed
the ‘grade 2 cut-point’ [15]. In the rest of this article we
have adopted similar terminology.
In three separate studies conducted by the authors of
the present article, investigators scored samples as positive
at the grade 1 cut-point in a similar way to each other. In
these studies, a positive result was defined as a band of
equal or greater intensity as the grade 1 cut-point. Visible
bands that were discernible but were weaker in intensity
than the grade 1 cut-point were scored as negative. In
two of the studies, results were also interpreted using
the grade 2 cut-point, but the two research groups used
slightly different definitions. Peter and colleagues defined
a positive result at the grade 2 cut-point by the presence
of a band of at least equal intensity to the grade 2 refer-
ence band. In contrast, Dorman and colleagues scored a
positive result at this cut-point as being the presence of
a band whose intensity was greater than that of a grade 1
band but closer in intensity to a grade 2 than a grade 1
band. Clearly, careful standardization of the reading meth-
odology is a critical need.
Using the grade 1 cut-point and a rigorous reference
standard of liquid culture on two sputum samples (spot
plus induced), Lawn and colleagues studying ambulatory
patients screened prior to starting ART found very high
specificity (98.6%; 95%CI, 97.0-99.5). Interim analysis of
data from a follow-on study among in-patients found
specificity a little lower using the grade 1 cut-point but
approximately 99% using the grade 2 cut-point [43]. In
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contrast, both studies by Peter and colleagues and Dorman
and colleagues found much more limited specificity using
the grade 1 cut-point and that the area under the receiver
operator characteristic (ROC) curve was greater using a
grade 2 cut-point (Table 1). Thus, switching from a
grade 1 to a grade 2 cut-point increased specificity sub-
stantially but was also associated with some loss of
sensitivity in a study from South Africa (specificity, 90%
vs. 99%, p = 0.009; sensitivity: 60% vs. 45%, p < 0.001) [15].
These differences were even more marked in the study
conducted in Uganda and South Africa in which the
sensitivity of grade 1 and grade 2 cut-points were 61.6%
and 37.1%, respectively, and the specificities were 78.4%
and 97.6%, respectively [16].
The apparent discrepancies between the optimum
cut-off in these studies may relate to a number of fac-
tors including differences in precisely how the strips were
interpreted, the reference standard used and differences
in patient populations. However, all investigators of these
three studies are in agreement that reading the strips at
the grade 1 cut-point is challenging and takes a great
degree of care that is unlikely to be a realistic expect-
ation of non-laboratory trained health-care workers in
the busy clinic environment. Thus, the authors suggest
that use of the grade 2 cut-point is more likely to pro-
vide a reproducible test result and be feasible to use in
clinical practice in the clinic environment. Future studies
of both diagnostic accuracy and operational feasibility
should evaluate both cut-offs to increase the evidence
base. The method used by Peter et al. would represent
the simplest approach and would potentially permit re-
sults to be read using visual comparison with a revised
version of the reference card displaying a single (grade 2
intensity) standard band. Positive results would then sim-
ply be defined by a test band of equal or greater intensity
as the single reference band.
8. Can this be used as a stand-alone test?
It is clear that Determine TB-LAM cannot be used as a
stand-alone test but has a potentially important role
as an add-on test within the diagnostic algorithm. Its
limited sensitivity requires that it is used in conjunction
with other diagnostic tests that collectively provide ad-
equate sensitivity for TB diagnosis as well as sufficiently
high negative predictive value to rule out TB. However,
data are emerging that Determine TB-LAM not only
provides the most rapid means of conducting an initial
diagnostic screen at the point-of-care, but also yields
incremental diagnostic sensitivity when combined with
sputum microscopy [12,15] and Xpert MTB/RIF testing
of sputum [16]. Moreover, it has high positive predictive
value among patients with abnormal chest radiographs
[12]. Studies need to define how to best use Determine
TB-LAM in combination with other assays within the
diagnostic algorithm to optimise diagnostic accuracy,
minimize time to diagnosis, reduce initial treatment
default and mortality and to provide the most efficient
and cost-effective diagnostic process.
9. What types of studies on determine TB-LAM are needed?
To date, most studies of Determine TB-LAM have assessed
diagnostic accuracy, with testing of stored urine samples
being done retrospectively. A series of coordinated studies
are now needed to:
i. increase the evidence base for the diagnostic
accuracy in the appropriate clinical populations;
ii. define the optimum methods of urine collection to
minimise the likelihood of urine contamination (and
optimimum storage if later retrospective analyses are
also to be done).
iii. assess the operational feasibility of prospective use of
the assay in the clinical environment;
iv. define at which levels of the health care system the
assay can be used and by which cadres of health
care workers;
v. define how to incorporate the assay into the
diagnostic algorithm;
vi. assess the impact of implementation of the assay on
clinical outcomes by means of randomised
controlled trials (one such trial is in progress: http://
clinicaltrials.gov/show/NCT01770730;
vii. assess cost-effectiveness in different settings and
algorithms.
viii. assess operational feasibility of use by national TB
control programmes, including systems for
reporting and surveillance.
Conclusion
The Determine TB-LAM assay offers the prospect of low-
cost point-of-care diagnosis of HIV-associated TB among
patients with advanced HIV-associated immunodeficiency
in whom mortality risk is greatest. Future studies on the
use of this as an add-on assay within diagnostic algorthims
require careful design and appropriate standardization to
build a strong evidence base for implementation.
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